

NPP4 (C-15): sc-248107

BACKGROUND

NPP4, also known as ENPP4 (ectonucleotide pyrophosphatase/phosphodiesterase family member 4), is a 453 amino acid single-pass type I membrane protein that belongs to the nucleotide pyrophosphatase/phosphodiesterase family. The gene that encodes NPP4 consists of approximately 16,736 bases and maps to human chromosome 6p21.1. Making up nearly 6% of the human genome, chromosome 6 contains around 1,200 genes within 170 million base pairs of sequence. Deletion of a portion of the q arm of chromosome 6 is associated with early onset intestinal cancer suggesting the presence of a cancer susceptibility locus. Porphyria cutanea tarda is associated with chromosome 6 through the HFE gene, and Stickler syndrome, 21-hydroxylase deficiency and maple syrup urine disease are also associated with genes on chromosome 6. Notably, the PARK2 gene, which is associated with Parkinson's disease, and the genes encoding the major histocompatibility complex proteins are also located on chromosome 6. A bipolar disorder susceptibility locus has been identified on the q arm of chromosome 6.

REFERENCES

1. Brunner, H.G., van Beersum, S.E., Warman, M.L., Olsen, B.R., Ropers, H.H. and Mariman, E.C. 1994. A Stickler syndrome gene is linked to chromosome 6 near the COL11A2 gene. *Hum. Mol. Genet.* 3: 1561-1564.
2. Gijbbers, R., Ceulemans, H., Stalmans, W. and Bollen, M. 2001. Structural and catalytic similarities between nucleotide pyrophosphatases/phosphodiesterases and alkaline phosphatases. *J. Biol. Chem.* 276: 1361-1368.
3. Cesari, R., Martin, E.S., Calin, G.A., Pentimalli, F., Bichi, R., McAdams, H., Trapasso, F., Drusco, A., Shimizu, M., Masciullo, V., D'Andrilli, G., Scambia, G., Picchio, M.C., Alder, H., Godwin, A.K. and Croce, C.M. 2003. Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. *Proc. Natl. Acad. Sci. USA* 100: 5956-5961.
4. Harel, T., Rabinowitz, R., Hendler, N., Galil, A., Flusser, H., Chemke, J., Gradstein, L., Lifshitz, T., Ofir, R., Elbedour, K. and Birk, O.S. 2005. COL11A2 mutation associated with autosomal recessive Weissenbacher-Zweymuller syndrome: molecular and clinical overlap with otospondyloomegaepiphyseal dysplasia (OSMED). *Am. J. Med. Genet. A* 132A: 33-35.
5. Bläker, H., Mechttersheimer, G., Sutter, C., Hertkorn, C., Kern, M.A., Rieker, R.J., Penzel, R., Schirmacher, P. and Kloor, M. 2008. Recurrent deletions at 6q in early age of onset non-HNPCC- and non-FAP-associated intestinal carcinomas. Evidence for a novel cancer susceptibility locus at 6q14-q22. *Genes Chromosomes Cancer* 47: 159-164.
6. Fan, J., Ionita-Laza, I., McQueen, M.B., Devlin, B., Purcell, S., Faraone, S.V., Allen, M.H., Bowden, C.L., Calabrese, J.R., Fossey, M.D., Friedman, E.S., Gyulai, L., Hauser, P., Ketter, T.B., Marangell, L.B., et al. 2010. Linkage disequilibrium mapping of the chromosome 6q21-22.31 bipolar I disorder susceptibility locus. *Am. J. Med. Genet. B Neuropsychiatr. Genet.* 153B: 29-37.
7. Jalil, S., Grady, J.J., Lee, C. and Anderson, K.E. 2010. Associations among behavior-related susceptibility factors in porphyria cutanea tarda. *Clin. Gastroenterol. Hepatol.* 8: 297-302.

CHROMOSOMAL LOCATION

Genetic locus: ENPP4 (human) mapping to 6p21.1; Enpp4 (mouse) mapping to 17 B3.

SOURCE

NPP4 (C-15) is an affinity purified goat polyclonal antibody raised against a peptide mapping within an N-terminal cytoplasmic domain of NPP4 of human origin.

PRODUCT

Each vial contains 200 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-248107 P, (100 µg peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

NPP4 (C-15) is recommended for detection of NPP4 of mouse and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000); non cross-reactive with NPP6.

NPP4 (C-15) is also recommended for detection of NPP4 in additional species, including equine, canine and bovine.

Suitable for use as control antibody for NPP4 siRNA (h): sc-95266, NPP4 shRNA Plasmid (h): sc-95266-SH and NPP4 shRNA (h) Lentiviral Particles: sc-95266-V.

Molecular Weight of NPP4: 52 kDa.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.